Jerrold L Boxerman1, Zheng Zhang2, Yair Safriel3, Jeffrey M Rogg1, Ronald L Wolf4, Suyash Mohan4, Helga Marques2, A Gregory Sorensen5,6, Mark R Gilbert7,8, Daniel P Barboriak9. 1. Department of Diagnostic Imaging, Rhode Island Hospital and Alpert Medical School of Brown University, Providence, Rhode Island. 2. Center for Statistical Sciences, Brown University, Providence, Rhode Island. 3. Pharmascan Clinical Trials and Radiology Associates of Clearwater-University of South Florida, Clearwater, Florida. 4. Department of Radiology, Neuroradiology Division, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania. 5. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Charlestown, Massachusetts. 6. IMRIS, Deerfield Imaging, Inc, Minnetonka, Minnesota. 7. Department of Neuro-oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 8. Neuro-Oncology Branch of the National Cancer Institute, National Institutes of Health, Bethesda, Maryland. 9. Department of Radiology, Duke University Medical Center, Durham, North Carolina.
Abstract
Background: ACRIN 6686/RTOG 0825 was a phase III trial of conventional chemoradiation plus adjuvant temozolomide with bevacizumab or without (placebo) in newly diagnosed glioblastoma. This study investigated whether changes in contrast-enhancing and fluid attenuated inversion recovery (FLAIR)-hyperintense tumor assessed by central reading prognosticate overall survival (OS). Methods: Two hundred eighty-four patients (171 men; median age 57 y, range 19-79; 159 on bevacizumab) had MRI at post-op (baseline) and pre-cycle 4 of adjuvant temozolomide (22 wk post chemoradiation initiation). Four central readers measured bidimensional lesion enhancement (2D-T1) and FLAIR hyperintensity at both time points. Changes from baseline to pre-cycle 4 for both markers were dichotomized (increasing vs non-increasing). Cox proportional hazards model and Kaplan-Meier survival estimates were used for inference. Results: Adjusting for treatment, increasing 2D-T1 (n = 262, hazard ratio [HR] = 2.07, 95% CI: 1.48-2.91, P < 0.0001) and FLAIR (n = 273, HR = 1.75, 95% CI: 1.26-2.41, P = 0.0008) significantly predicted worse OS. Median OS (days) was significantly shorter for patients with increasing versus non-increasing 2D-T1 for both bevacizumab (443 vs 535, P = 0.004) and placebo (526 vs 887, P = 0.001). Median OS was significantly shorter for patients with increasing versus non-increasing FLAIR for placebo (595 vs 872, P = 0.001), and trended similarly for bevacizumab (499 vs 535, P = 0.0935). Adjusting for 2D-T1 and treatment, increasing FLAIR represented significantly higher risk for death (HR = 1.59 [1.11-2.26], P = 0.01). Conclusion: Increased 2D-T1 significantly predicts worse OS in both treatment groups, implying absence of a substantial proportion of pseudoprogression 22 weeks after initiation of standard therapy. FLAIR adds value beyond 2D-T1 in predicting OS, potentially addressing the pseudoresponse effect by substratifying bevacizumab-treated patients with non-increasing 2D-T1.
RCT Entities:
Background: ACRIN 6686/RTOG 0825 was a phase III trial of conventional chemoradiation plus adjuvant temozolomide with bevacizumab or without (placebo) in newly diagnosed glioblastoma. This study investigated whether changes in contrast-enhancing and fluid attenuated inversion recovery (FLAIR)-hyperintense tumor assessed by central reading prognosticate overall survival (OS). Methods: Two hundred eighty-four patients (171 men; median age 57 y, range 19-79; 159 on bevacizumab) had MRI at post-op (baseline) and pre-cycle 4 of adjuvant temozolomide (22 wk post chemoradiation initiation). Four central readers measured bidimensional lesion enhancement (2D-T1) and FLAIR hyperintensity at both time points. Changes from baseline to pre-cycle 4 for both markers were dichotomized (increasing vs non-increasing). Cox proportional hazards model and Kaplan-Meier survival estimates were used for inference. Results: Adjusting for treatment, increasing 2D-T1 (n = 262, hazard ratio [HR] = 2.07, 95% CI: 1.48-2.91, P < 0.0001) and FLAIR (n = 273, HR = 1.75, 95% CI: 1.26-2.41, P = 0.0008) significantly predicted worse OS. Median OS (days) was significantly shorter for patients with increasing versus non-increasing 2D-T1 for both bevacizumab (443 vs 535, P = 0.004) and placebo (526 vs 887, P = 0.001). Median OS was significantly shorter for patients with increasing versus non-increasing FLAIR for placebo (595 vs 872, P = 0.001), and trended similarly for bevacizumab (499 vs 535, P = 0.0935). Adjusting for 2D-T1 and treatment, increasing FLAIR represented significantly higher risk for death (HR = 1.59 [1.11-2.26], P = 0.01). Conclusion: Increased 2D-T1 significantly predicts worse OS in both treatment groups, implying absence of a substantial proportion of pseudoprogression 22 weeks after initiation of standard therapy. FLAIR adds value beyond 2D-T1 in predicting OS, potentially addressing the pseudoresponse effect by substratifying bevacizumab-treated patients with non-increasing 2D-T1.
Authors: Alexander Radbruch; Kira Lutz; Benedikt Wiestler; Philipp Bäumer; Sabine Heiland; Wolfgang Wick; Martin Bendszus Journal: Neuro Oncol Date: 2011-12-06 Impact factor: 12.300
Authors: L C Hygino da Cruz; I Rodriguez; R C Domingues; E L Gasparetto; A G Sorensen Journal: AJNR Am J Neuroradiol Date: 2011-03-10 Impact factor: 3.825
Authors: Mark R Gilbert; James J Dignam; Terri S Armstrong; Jeffrey S Wefel; Deborah T Blumenthal; Michael A Vogelbaum; Howard Colman; Arnab Chakravarti; Stephanie Pugh; Minhee Won; Robert Jeraj; Paul D Brown; Kurt A Jaeckle; David Schiff; Volker W Stieber; David G Brachman; Maria Werner-Wasik; Ivo W Tremont-Lukats; Erik P Sulman; Kenneth D Aldape; Walter J Curran; Minesh P Mehta Journal: N Engl J Med Date: 2014-02-20 Impact factor: 91.245
Authors: Martin J van den Bent; Michael A Vogelbaum; Patrick Y Wen; David R Macdonald; Susan M Chang Journal: J Clin Oncol Date: 2009-05-18 Impact factor: 44.544
Authors: Corinne Beinat; Chirag B Patel; Tom Haywood; Surya Murty; Lewis Naya; Jessa B Castillo; Samantha T Reyes; Megan Phillips; Pablo Buccino; Bin Shen; Jun Hyung Park; Mary Ellen I Koran; Israt S Alam; Michelle L James; Dawn Holley; Kim Halbert; Harsh Gandhi; Joy Q He; Monica Granucci; Eli Johnson; Daniel Dan Liu; Nobuko Uchida; Rahul Sinha; Pauline Chu; Donald E Born; Geoffrey I Warnock; Irving Weissman; Melanie Hayden-Gephart; Mehdi Khalighi; Tarik F Massoud; Andrei Iagaru; Guido Davidzon; Reena Thomas; Seema Nagpal; Lawrence D Recht; Sanjiv Sam Gambhir Journal: Clin Cancer Res Date: 2021-09-02 Impact factor: 13.801
Authors: Benjamin B Kasten; Neha Udayakumar; Jianmei W Leavenworth; Anna M Wu; Suzanne E Lapi; Jonathan E McConathy; Anna G Sorace; Asim K Bag; James M Markert; Jason M Warram Journal: Theranostics Date: 2019-07-09 Impact factor: 11.556
Authors: Kathleen M Schmainda; Melissa A Prah; Helga Marques; Eunhee Kim; Daniel P Barboriak; Jerrold L Boxerman Journal: Neuro Oncol Date: 2021-02-25 Impact factor: 13.029